Advertisement

Advertisement

CRVO Stock Latest News

3 Best Stocks to Buy Today, According to Top Wall Street Analysts – Sept. 29

Market News3 Best Stocks to Buy Today, According to Top Wall Street Analysts – Sept. 29

CervoMed Advances Neflamapimod Tablet and Dosing Strategy

PremiumCompany Announcements

CervoMed Advances Neflamapimod Tablet and Dosing Strategy

3d ago

PremiumRatings

CervoMed: Improved Dosing, Safety Margin and CMC Profile Bolster Confidence in 100 mg BID Regimen; Buy Rating and $12 Price Target Reiterated

4d ago

CervoMed neflamapimod update removes key overhang, says Jones

PremiumThe Fly

CervoMed neflamapimod update removes key overhang, says Jones

4d ago

CervoMed announces PK results with new neflamapimod oral tablet formula

PremiumThe Fly

CervoMed announces PK results with new neflamapimod oral tablet formula

4d ago

CervoMed highlights late-breaking neflamapimod Phase 2a data

PremiumCompany AnnouncementsCervoMed highlights late-breaking neflamapimod Phase 2a data

21d ago

CervoMed price target lowered to $7 from $9 at Roth Capital

The Fly

CervoMed price target lowered to $7 from $9 at Roth Capital

1M ago

CervoMed: Buy Rating Reiterated as Dementia Pipeline Advances; $25 Price Target Maintained

Ratings

CervoMed: Buy Rating Reiterated as Dementia Pipeline Advances; $25 Price Target Maintained

2M ago

Analyst Maintains Buy on CervoMed, Cuts Target to $12 Amid Updated Launch Assumptions but Sees $3B Peak Sales Potential

PremiumRatings

Analyst Maintains Buy on CervoMed, Cuts Target to $12 Amid Updated Launch Assumptions but Sees $3B Peak Sales Potential

2M ago

CervoMed price target lowered to $18 from $27 at Canaccord

PremiumThe Fly

CervoMed price target lowered to $18 from $27 at Canaccord

2M ago

CervoMed’s neflamapimod gains UK Innovation Passport

PremiumCompany Announcements

CervoMed’s neflamapimod gains UK Innovation Passport

2M ago

CervoMed advances neflamapimod strategy with new DLB data

PremiumCompany Announcements

CervoMed advances neflamapimod strategy with new DLB data

3M ago

CervoMed Completes Enrollment in Phase 2a Neflamapimod Trial

PremiumCompany AnnouncementsCervoMed Completes Enrollment in Phase 2a Neflamapimod Trial

3M ago

CervoMed completes enrollment in neflamapimod study

The Fly

CervoMed completes enrollment in neflamapimod study

3M ago

CervoMed’s DLB Trial Milestone: What CRVO Investors Should Watch Next

Company Announcements

CervoMed’s DLB Trial Milestone: What CRVO Investors Should Watch Next

3M ago

CervoMed registers to sell 10.08M shares of common stock for holders

PremiumThe Fly

CervoMed registers to sell 10.08M shares of common stock for holders

3M ago

CervoMed Raises $10 Million in Direct Offering

PremiumCompany Announcements

CervoMed Raises $10 Million in Direct Offering

3M ago

CervoMed announces $10M registered direct offering priced at-the-market

PremiumThe Fly

CervoMed announces $10M registered direct offering priced at-the-market

4M ago

CervoMed Gains New Patent for Neflamapimod Dementia Therapy

PremiumCompany Announcements

CervoMed Gains New Patent for Neflamapimod Dementia Therapy

4M ago

CervoMed receives notice of allowance from USPTO on neflamapimod

PremiumThe FlyCervoMed receives notice of allowance from USPTO on neflamapimod

4M ago

CervoMed Posts Updated Investor Presentation and Business Overview

Company Announcements

CervoMed Posts Updated Investor Presentation and Business Overview

4M ago

CervoMed Announces Private Placement to Advance Neurology Pipeline

Company Announcements

CervoMed Announces Private Placement to Advance Neurology Pipeline

4M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >